Variable | Treatment group (dose of AZD0530) | ||||
---|---|---|---|---|---|
Placebo (n = 6) | 50 mg (n = 6) | 100 mg (n = 6) | 125 mg (n = 6) | F P | |
Age | 72.6 ± 9.5 | 72.6 ± 4.4 | 71.5 ± 4.9 | 4.6 ± 7.9 | 0.57 † 0.19 |
Sex | 3 F, 3 M | 5 F, 1 M | 2 F, 4 M | 3 F, 3 M | |
Education (years) | 15.0 ± 2.8 | 15.3 ± 2.7 | 14.3 ± 2.3 | 16.8 ± 3.4 | 0.84 † 0.49 |
Weight (kg) | 6.88 ± 12.1 | 69.7 ± 8.7 | 79.6 ± 17.9 | 65.4 ± 10.4 | 1.37 † 0.28 |
MMSE, baseline | 23.0 ± 4.1 | 21.8 ± 3.3 | 22.2 ± 4.6 | 20.2 ± 2.3 | 0.63 † 0.60 |
MMSE, week 4 | 25.7 ± 3.3 | 25.3 ± 2.4 | 22.7 ± 4.0 | 22.5 ± 3.3 | |
MMSE, change | 2.7 ± 2.0 | 3.5 ± 1.9 | 0.5 ± 3.4 | 2.3 ± 2.1 | 2.15 § 0.13 |
ADAS-cog, baseline | 16.7 ± 2.3 | 20.6 ± 6.7 | 23.8 ± 4.5 | 21.6 ± 7.1 | 1.73 † 0.19 |
ADAS-cog, week 4 | 15.2 ± 4.8 | 18.3 ± 4.5 | 22.3 ± 8.1 | 23.0 ± 4.4 | |
ADAS-cog, change | −1.6 ± 4.4 | −2.3 ± 3.4 | −1.4 ± 5.4 | 1.4 ± 3.2 | 1.31 § 0.30 |
ADCS- ADL, baseline | 63.5 ± 9.2 | 68.7 ± 6.8 | 67.2 ± 6.4 | 64.8 ± 3.1 | 0.67 † 0.58 |
ADCS- ADL, week 4 | 67.7 ± 10.6 | 66.5 ± 6.7 | 68.2 ± 7.6 | 66.4 ± 4.3 | |
ADCS- ADL, change | 4.2 ± 5.2 | −2.2 ± 4.2 | 1.0 ± 2.0 | 1.6 ± 3.4 | 2.27 ‡ 0.12 |
CDR-SOB, baseline | 5.6 ± 2.2 | 5.3 ± 1.9 | 4.8 ± 1.2 | 5.1 ± 1.8 | 0.22 † 0.88 |
CDR-SOB, week 4 | 5.8 ± 2.4 | 5.0 ± 1.9 | 4.8 ± 1.2 | 5.6 ± 1.9 | |
CDR-SOB, change | 0.2 ± 0.4 | −0.3 ± 0.6 | 0.0 ± 0.0 | 0.5 ± 0.4 | 2.60 ‡ 0.08 |
NPI, baseline | 9.5 ± 11.9 | 6.5 ± 6.1 | 3.7 ± 4.3 | 13.2 ± 10.1 | ¶ 0.37 |
NPI, week 4 | 4.0 ± 5.0 | 7.7 ± 9.1 | 2.5 ± 3.5 | 18.0 ± 8.9 | |
NPI, change | −5.5 ± 8.4 | 1.2 ± 5.1 | −1.2 ± 4.8 | 4.8 ± 7.6 | ¶ 0.09 |